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a b s t r a c t
Background: Interferon gamma release assays (IGRAs) are used to detect latent Mycobacterium tuberculosis (M.tb) infection (LTBI) in adults, but their performance in older people is not well-established. We
evaluated IGRAs for LTBI detection in older Hispanic recent TB contacts (ReC) or community controls
(CoC).
Methods: Cross-sectional assessment of LTBI with T-SPOT.TB and/or QuantiFERON-Gold in-tube or –Plus
assay in older (≥60 years) and adult (18–50 years) Hispanic people.
Results: We enrolled 193 CoC (119 adults, 74 older persons) and 459 ReC (361 adults, 98 older persons).
LTBI positivity increased with age in CoC (19%–59%, P<0.001), but was similar in ReC (59%–69%, P=0.329).
Older people had lower concordance between IGRAs (kappa 0.465 vs 0.688 in adults) and more inconclusive results (indeterminate/borderline 11.6% vs 5.8% in adults, P=0.012). With simultaneous IGRAs, inconclusive results were resolved as positive or negative with the other IGRA. The magnitude of response
to M.tb peptides in IGRAs was similar among age groups, but responsiveness to mitogens was lower in
older people.
Conclusions: IGRAs are suitable for LTBI detection in older people. Discordant and inconclusive ﬁndings
are more prevalent in older people, but results are resolved when IGRA is repeated with a different IGRA
test.
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)

INTRODUCTION
Mycobacterium tuberculosis (M.tb) infected nearly 10 million
people and caused 1.8 million tuberculosis (TB) deaths worldwide

Abbreviations: IGRAs, Interferon gamma release assays; LTBI, latent Mycobacterium tuberculosis infection; TB, tuberculosis; ReC, recent TB contacts; CoC, community controls; QFT, QuantiFERON; TST, tuberculin skin test.
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Campus, Edinburg, TX, USA
E-mail address: Blanca.i.restrepo@uth.tmc.edu (B.I. Restrepo).
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in 2020. (World-Health-Organization 2020) An estimated onequarter of the world’s population has a latent Mycobacterium tuberculosis (M.tb) infection (LTBI), with 5%–10% anticipated to develop
TB disease over their lifetime. (Houben and Dodd, 2016) Older people have a 1.5-fold risk of progressing to TB when compared with
adults, and are prone to poor treatment outcomes with 20%–30%
mortality. (Hochberg and Horsburgh, 2013, Abdelbary et al., 2017,
Garcia-Goez et al., 2020) TB risk factors in older people include
a higher prevalence of LTBI and a dysfunctional immune system
marked by inﬂammaging and oxidative stress. (Hochberg and Horsburgh, 2013, Piergallini and Turner, 2018) Higher LTBI prevalence in

https://doi.org/10.1016/j.ijid.2021.08.014
1201-9712/© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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IFN-γ response of blood CD4 T-cell lymphocytes to M.tb antigens
ESAT-6 (panel A) or CFP-10 (Panel B), while the QFT-GIT evaluates these responses to the M.tb antigens ESAT-6, CFP-10, and
TB7.7 (TB1). (QuantiFERON-TB Gold 2006) The QFT-Plus contains a
second tube with M.tb peptides that stimulate CD8 T-cells (TB2).
(QuantiFERON-TB Gold Plus (QFT-Plus) Package Insert 2020) During this study, Qiagen transitioned from the QuantiFERON Gold Intube (QFT-GIT) to QFT-Plus (collectively referred to as QFT), with
most participants tested with the QFT-Plus version (399 of 524 participants, 76.1%). We did not ﬁnd differences in their performance
(Figure S1). Per manufacturer instructions, QFTs with low mitogen
responses or high backgrounds were categorized as indeterminate
(QuantiFERON-TB Gold Plus (QFT-Plus) Package Insert 2020) and TSPOT.TBs with 5–7 spots after subtraction of the negative control
from the highest of panels A or B were categorized as borderline.
(T-SPOT.TB Package insert 2017) When there was a borderline result with T-SPOT.TB or an indeterminate with QFT (i.e., inconclusive results), the positive or negative result with the other IGRA
determined the ﬁnal LTBI diagnosis.

older people is largely attributed to their lifetime-accumulated risk
of exposure to M.tb. (Dutt and Stead, 1993)
LTBI detection is based on immunological memory to M.tb peptides, measured using the tuberculin skin test (TST) in vivo or
interferon gamma release assays (IGRAs) ex vivo. The TST detects recall immunity to intradermal M.tb puriﬁed protein derivative antigens. (Vukmanovic-Stejic et al., 2006) IGRAs are based
on interferon(IFN)-γ production by peripheral blood mononuclear cells (PBMCs) in response to speciﬁc M.tb peptides. (TSPOT.TB Package insert 2017, QuantiFERON-TB Gold (QFT) ELISA
Package Insert 2016, QuantiFERON-TB Gold 2006)
Interpretation of TST and IGRAs has been challenging in older
people due to several factors. First, TST sensitivity is reported
to decrease with older age (Dorken et al., 1987) with higher
false-negatives likely due to reduced skin immunity with aging.
(Agius et al., 2009, Zevallos and Justman, 2003) Second, LTBI is
highly heterogeneous in older people due to a range of recent or
remote exposures to pulmonary TB patients. Third, studies comparing the performance of TST vs IGRAs (T-SPOT.TB vs QuantiFERONs) show conﬂicting results, with most reporting lower sensitivity of the TST, and among IGRAs a higher sensitivity of the TSPOT.TB vs QuantiFERONs. (Ferrara et al., 2009, Bae et al., 2016,
Kobashi et al., 2009) When using active TB as a gold standard,
most studies report lower sensitivity in older people with all assays. However, these studies are limited by their focus on hospitalized and severely ill patients (Bae et al., 2016, Kobashi et al., 2009,
Kwon et al., 2015, Jeon et al., 2013), their use of QuantiFERON kit
versions that are no longer commercially available, and their targeting of older Asian patients without data from Hispanic patients.
To assess the performance of IGRAs for LTBI detection in older
Hispanic people, we conducted a cross-sectional study comparing
T-SPOT.TB and QuantiFERONs. We enrolled older people community controls or contacts of recent TB patients, with similar groups
of younger adults as reference. Our ﬁndings indicated a higher proportion of discordant, borderline or indeterminate ﬁndings in older
people, but these inconclusive results were always resolved as positive or negative with the other IGRA. LTBI prevalence was similar
with both IGRAs, and increased with age in the community controls, suggesting that IGRAs are suitable for assessing LTBI in older
people. We provide further insight into the clinical interpretation
of a positive IGRA in older people.

Data analysis
Data were analyzed using SAS v 9.4 (Cary, North Carolina). Chisquare or Fisher’s exact tests were used to compare categorical
variables. Median values were compared with the Wilcoxon rank
sum test. Comparisons of medians between more than 2 study
groups were established by the Kruskal-Wallis test with the post
hoc Dwass, Steel, Critchlow-Fligner method. The Cochran-Armitage
trend test was used to assess signiﬁcant changes over different age
groups. Cohen’s kappa coeﬃcient (k) was used to measure overall
agreement between paired test results. (McHugh, 2012) P values
were considered signiﬁcant if ≤0.05 and borderline signiﬁcant if
<0.10. Graphs were plotted using GraphPad PRISM v 9.0.
RESULTS
IGRA prevalence across age groups
We enrolled 652 participants: 193 CoC (119 adults; 74 older
people) and 459 ReC (361 adults; 98 older people), with sociodemographic and clinical characteristics similar to a subset of this
cohort recently described (Table S1). (Scordo et al., 2021) CoC
differed from ReC in their higher level of education (P=0.001),
prevalence of macrovascular disease (P<0.001) and total cholesterol levels (P=0.038; Table S1). LTBI prevalence was signiﬁcantly
higher among older people vs adults in the CoC group (56.7% in
older people vs 23.2% in adults; P<0.001), but similar between
age groups of ReC (older people 71.3% vs adults 64.1%; P=0.233;
Table 1). We found several host characteristics associated with LTBI
by univariate analysis, including hyperglycemia (P=0.045) and diabetes (P=0.063) in adults, and lower education level (P=0.013) and
macrovascular disease (P=0.080) in older people (Table 1). By multivariable analysis, hyperglycemia or diabetes were no longer associated. LTBI was independently associated with lower education
among all study participants (adjusted odds ratio (adj-OR) 1.71;
95% CI 1.55, 2.53), or with macrovascular disease among LTBI older
people in the ReC group (adj-OR 2.14, 95% CI 1.11, 4.12; Table S2).
(Scordo et al., 2021)
Next, we evaluated how LTBI prevalence changes with increasing age in CoC vs ReC groups by 10-year age intervals. For this
analysis, we also included CoC and ReC 51–59 years old (n= 111;
Supplemental material). Results are shown for when both IGRAs
are completed in Fig. 1 (T-SPOT.TB and QFT) or for the T-SPOT.TB
and QFTs alone in Figure S2. IGRA positivity increased with older
age among CoC (P<0.001) but remained consistently higher than
60% throughout all the studied ages in the ReC group (P=0.329).

METHODS
Participant enrollment
We enrolled adults (18–50 years) and older people (>60 years)
in south Texas and northeastern Mexico between 2017 and 2021,
consisting of an extended participant cohort recently described.
(Scordo et al., 2021) The cohort included: 1) individuals attending
pulmonary clinics due to recent exposure to newly diagnosed TB
patients for at least 5 hours within 6 months of enrollment (recent contacts; ReC); and 2) a convenience sample of community
controls (CoC) with no reported exposure or a remote history of
exposure (>6 months before enrollment) to a TB case. In addition,
we enrolled individuals 51–59 years old, with the same enrollment
and classiﬁcation criteria as those mentioned for ReC or CoC. This
study was approved by human subjects institutional review boards
in Mexico (110/2018/CEI) and the United States (HSC-SPH-19-0308),
and all participants signed written informed consent.
IGRAs
Blood was collected at the time of enrollment and simultaneously evaluated for LTBI with T-SPOT.TB (Oxford Immunotec) and a
QuantiFERON test (Qiagen, Germantown). T-SPOT.TB evaluates the
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Table 1
LTBI test results among older people and young adults, by exposure history
Community + Recent contacts

Community

Young adults
n (%)

Young adults
n (%)

Elderly
n (%)

P value

Recent contacts
Elderly
n (%)

Young adults
n (%)

Elderly
n (%)

127 (35.2)
234 (64.8)

32 (32.7)
66 (67.4)

138 (38.3)
205 (56.9)
17 (4.7)

35 (35.7)
53 (54.1)
10 (10.2)

115 (37.3)
184 (59.7)
9 (2.9)

28 (30.8)
57 (62.6)
6 (6.6)

26 (7.2)
17 (4.7)
9 (2.9)

17 (17.3)
10 (10.2)
6 (6.6)

<0.001

a

Conclusive (T-SPOT.TB and QFT complement)
0.075
Negative
219 (45.6)
65 (37.8)
92 (77.3)
Positive
261 (54.4)
107 (62.2)
27 (22.7)
T-SPOT.TB
0.264
Negative
230 (48.0)
72 (42.9)
92 (77.3)
85 (50.6)
25 (21.0)
Positive
230 (48.0)
Borderline
19 (4.0)
11 (6.6)
2 (1.7)
QFT (QFT-Gold In-tube or QFT-Plus)
0.117
Negative
173 (46.0)
58 (39.5)
58 (85.3)
Positive
194 (51.6)
81 (55.1)
10 (14.7)
Indeterminate
9 (2.4)
8 (5.4)
0 (0.0)
Inconclusive (borderline or indeterminate) vs conclusive (positive and negative combined)b
Borderline or indeterminate
28 (5.8)
20 (11.6)
0.012
2 (1.7)
Borderline
19 (4.0)
11 (6.6)
0.171
2 (1.7)
Indeterminate
9 (2.4)
8 (5.4)
0.077
0 (0.0)

P value

33 (44.6)
41 (55.4)

0.641

0.002
37 (52.9)
32 (45.7)
1 (1.4)

0.124

<0.001
30 (53.6)
24 (42.9)
2 (3.6)
3 (4.0)
1 (1.4)
2 (3.6)

0.313
0.893
0.116

P value

0.177

0.002
0.041
0.106

a
LTBI was positive when the T-SPOT.TB or QuantiFERON (QFT) assays (Gold In-tube or QuantiFERON-Plus) were positive. Borderline or indeterminate results were complemented with the positive or negative ﬁnding from the other IGRA.
b
Comparisons of negative and positive values combined (conclusive) vs borderline or indeterminate or both types of inconclusive results combined. Differences between
groups established by Chi-square test. Signiﬁcant or borderline signiﬁcant differences are shown in bold text.

Fig. 1. Changes in the prevalence of IGRA-positive results across age groups. The
prevalence of LTBI was based on a positive T-SPOT.TB or QuantiFERON assay (QFTGIT or QFT-Plus). The prevalence of LTBI increased with age among the CoC
(P=<0.001) but not for ReC (P=0.354). LTBI was signiﬁcantly higher among CoC vs
ReC until aged 59 (non-overlapping 95% CIs) but not among those aged ≥60 years.
The proportion of newly-infected individuals in the ReC groups was calculated by
subtracting LTBI-positives from the baseline CoC group (line with triangles).
CoC, Community controls; ReC, Recent contacts; LTBI, latent M. tuberculosis infection. Vertical bars, 95% CIs for LTBI prevalence. IGRA, Interferon-gamma release assay; QFT, QuantiFERON-Gold In-Tube and -Plus

Fig. 2. Concordance between IGRA assays, by age and study groups. The percentage
of positive and negative agreement was estimated for participants in whom both
types of IGRA assays were carried out simultaneously (n=518 of 652, 79.4%) by age
and study group. The sample size and kappa statistic (k) is provided for each study
group.
CoC, Community controls; ReC, Recent contacts.IGRA, Interferon-gamma release assay

Our results also indicated that the proportion of new M.tb infections among ReC was signiﬁcantly higher in adults (mean 39.2%,
95% CIs 29.6%, 48.8%) compared with older people (mean 11.4%,
95% CI 5.2, 17.6%; P<0.050; Fig. 1). In summary, IGRA positivity increased with age in older age CoC but remained consistently higher
throughout all the age groups in the ReC.
Concordance between IGRA assays

(kappa 0.478, weak) vs 83.8% in adults (kappa 0.695, moderate).
When age groups were further stratiﬁed by CoC or ReC, IGRAs
from older people had a lower concordance compared with adults
(CoC kappa: 0.342 vs 0.719 in adults; ReC kappa: 0.532 vs 0.660 in
adults; Fig. 2; Table S3). Agreement was lower for the CoC vs ReC,
and particularly low in older people (CoC: 65.4.2%, kappa 0.342,
minimal; ReC: 74.8%, kappa 0.532, weak). In summary, the proportion of discordant results was highest among older people, and
particularly in the CoC group (34.6%, Fig. 2).

The proportion of older people who tested IGRA positive was
similar for T-SPOT.TB and QFT assays: 45.7% vs 42.9% in the CoC
group and 54.1% vs 62.6% in the ReC group (Table 1). Among participants tested simultaneously with both types of IGRA (518 of
652 participants, 79.4%) in both the CoC and ReC groups, the overall concordance between IGRAs was 80.4% (kappa 0.694, moderate; Fig. 2; Table S3). However, agreement between IGRAs differed
by age group. Among all older people, the concordance was 71.4%
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Fig. 3. Resolution of inconclusive IGRAs. A. Among all study participants, borderline T- SPOT.TB was positive in 50% (14 of 28) of the cases by QFT, while indeterminate QFTs
were positive by T- SPOT.TB in 100% (17 of 17) of the cases. B. Among all older participants, borderline T- SPOT.TB was positive in 64% (7 of 11) of the cases by QFT, while
indeterminate QFTs were positive by T- SPOT.TB in 100% (8 of 8) of the cases.

had fewer lymphocytes responses to the ESAT-6 antigen (P=0.05),
but all other responses to M.tb antigens were similar among age
groups. The only consistent difference in older people vs adults
was their lower responsiveness to mitogens in the QFT-Plus assay
in the CoC (P=0.064) and ReC (P=0.073). These ﬁndings were conﬁrmed when expanding our analyses to all study participants since
the response to mitogens was not affected by the positivity of the
IGRA (CoC P<0.001; ReC P=0.035). Finally, we found that regardless of age, recent exposure to a TB patient (ReC group) was associated with higher IFN-γ secretion vs remote exposure (CoC group;
Table S4). In summary, older age was associated with lower responses to mitogens, while the timing since exposure to an active
TB case inﬂuenced the magnitude of the response to M.tb antigens.

To determine the contribution of inconclusive results (indeterminate with QFTs or borderline with T-SPOT.TB) to the discordance
between IGRAs, we excluded participants with inconclusive results
and re-evaluated the data. The concordance between IGRAs improved in nearly all study groups (Table S3). Among all participants, the agreement improved by 7.5% (from 80.4% to 87.9% after
exclusions). The largest improvement was among older ReC (from
74.4% to 89.2%), the study group with the highest risk of TB.
Interpretation of inconclusive results
Given the contribution of borderline or indeterminate results to
the discordance between IGRAs, we expanded these analyses. Participants with borderline T-SPOT.TB results (n=28 of 30) and indeterminate QFT results (n=17 of 17) were tested with both IGRAs simultaneously. In all cases, the other IGRA resolved the inconclusive
ﬁndings, with all participants having a deﬁned ﬁnal classiﬁcation
of positive or negative LTBI (upper panel of Table 1). In comparison, if only one IGRA were performed per participant, older people
would have had a higher proportion of borderline results with the
T-SPOT.TB (6.6% vs 4.0%) or indeterminate results with the QFTs
when compared with adults (5.4% vs 2.4%; Table 1). When combining both types of observations, these inconclusive results (borderline + indeterminate results) were signiﬁcantly higher among
older ReC (17.3% vs 7.2% adults; P=0.002), and there was a similar
trend for the smaller CoC group (older people 4.0% vs 1.7% adults;
P=0.179; Table 1). Thus, older individuals had a higher likelihood
of an inconclusive LTBI result than adults.
We next determined if inconclusive results were more likely to
be resolved as positive or negative with the complementary IGRA
(Fig. 3A-B). We found that a borderline T-SPOT.TB result was resolved as positive with the QFT in at least half the cases (14 of
28, 50% in adults; 7 of 11, 63.6% in older people; Fig. 3). In contrast, an indeterminate result by QFT was resolved as positive with
the T-SPOT.TB in 100% of the cases: 17 of 17 participants tested, including 8 of 8 older people. In all cases, indeterminate results were
due to high IFN-γ background. In summary, borderline T-SPOT.TB
results were true borderline, while indeterminate QFT results were
always positive with the T-SPOT.TB.

DISCUSSION
We evaluated the performance of IGRAs among Hispanic older
people vs adults in ReC and CoC groups. This design allowed us to
compare the performance of the T-SPOT.TB and QFT assays across
age groups, and among participants, with recent vs remote exposure to active TB cases. Our design contrasts with most previous
studies, where IGRAs were evaluated among active TB cases across
age groups, or as part of outbreak investigations among older people. (Ferrara et al., 2009, Bae et al., 2016, Kobashi et al., 2009)
Furthermore, our analysis was done with QFT-Plus, in contrast to
previous studies that evaluated earlier versions of QFT. (Bae et al.,
2016, Kobashi et al., 2009, Xin et al., 2019)
There is a concern that the decline in the strength of the
immune response in older people may decrease the sensitivity
of assays to detect LTBI in this population. (Byng-Maddick and
Noursadeghi, 2016) This limitation is observed for the TST
(Dorken et al., 1987, Kobashi et al., 2009), with a higher proportion of false negatives attributed to compromised skin immunity
in older people. (Agius et al., 2009) A lower sensitivity has also
been reported for IGRAs in older people, although less marked
than with the TST. However, these observations are from studies
conducted amongst active TB patients, and with false-negatives associated with very advanced TB disease, lymphopenia or malnutrition. (Bae et al., 2016, Kobashi et al., 2009, Tebruegge et al.,
2014) Evaluation of IGRAs in older people with TB in these studies
may differ from results we obtained in those without TB for several reasons. First, our older participants did not have severe underlying conditions that could compromise their immunity, other
than a high prevalence of diabetes that was not associated with
their LTBI status (Table S2). Second, previous studies in participants
with TB also reported higher indeterminate results in older people,
but these were due to low mitogen responses (Jeon et al., 2013,
Tebruegge et al., 2014), while our indeterminate results were due
to high IFN-γ background. Third, we observed an increasing preva-

IFN-γ response among LTBI participants
We evaluated differences in the magnitude of response to M.tb
antigens (number of IFN-γ positive lymphocytes by T-SPOT.TB, or
IFN-γ titers by QFT-Plus) by age group. Since the proportion of
IGRA-positives was higher in older people, the analysis was limited to those positive with any assay. In the CoC group, there were
no differences in the magnitude of IGRA responses to M.tb antigens among age groups (Table 2). In the ReC group, older people
88
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Table 2
Magnitude of IGRA responses among participants positive for LTBI

a,b

Community
Adults

T-SPOT.TB
Nil
ESAT6 - Nil
CFP10 - Nil
QFT-Plus
Nil
Mit-Nil
TB1 - Nil
TB2 - Nil
Mit-Nil (all)

c

Recent contacts
Elderly

Adults

Elderly

n

Median (IQR)

n

Median (IQR)

P

n

Median (IQR)

n

Median (IQR)

P

29
29
29

0 (0.0)
10 (21.0)
16 (18.0)

42
42
42

0 (1.0)
10.5 (17)
20 (20)

0.281
0.760
0.767

244
244
244

0 (1.0)
18 (19.0)
22 (17.0)

69
69
69

0 (0.0)
10 (17.0)
22 (20.0)

0.023
0.050
0.998

14
14
14
14
53

0.2 (0.6)
21.4 (16.0)
0.4 (10.2)
0.5 (8.2)
25.6 (13.9)

31
31
31
31
56

0.2 (0.6)
15.4 (15.5)
0.6 (1.8)
0.7 (2.5)
15.5 (3.6)

0.787
0.064
0.806
0.902
<0.001

139
139
139
139
219

0.4 (1.4)
21.0 (11.6)
4.2 (6.6)
4.1 (7.1)
21.3 (11.5)

44
44
44
44
71

0.5 (1.8)
15.5 (15.5)
3.8 (6.5)
3.9 (6.5)
16.1 (14.4)

0.764
0.073
0.436
0.349
0.035

a

Participants with positive IGRAs included those with borderline or indeterminate results who were classiﬁed as positive based on the other IGRA assay
Values from the indeterminate reactions were excluded due to their high non-speciﬁc IFN-γ background;
Mitogen responses were also evaluated for all study participants, including those who tested IGRA-negative;Mit, mitogen; Group medians were compared
by the Wilcoxon rank sum test; Statistically signiﬁcant or borderline signiﬁcant differences are in bold text. IGRA, Interferon-gamma release assay; QFT, QuantiFERON; Nil, negative control; IQR, interquartile range; All, indicates all participants analyzed
b
c

lence of LTBI positives with age, even among individuals older than
60 (Fig. 1). However, we did not have a gold standard for TB infection since active TB patients were not studied, and hence, we
cannot rule out a lower sensitivity of the IGRA assays in the oldest participants (≥70 years). We think lower sensitivity is unlikely
because we did not detect a notable reduction in the magnitude
of the cell-mediated immune responses to M.tb antigens in older
people compared with adults (Table 2), and the prevalence of LTBI
was similar when using T-SPOT.TB vs QFTs (Figure S2C). Together,
our results suggest that the sensitivity of IGRAs for the detection
of LTBI cases is not signiﬁcantly impacted by old age alone.
Previous studies report challenges with IGRAs in older people vs adults, namely poorer concordance between IGRAs, or between IGRAs and the TST. (Ferrara et al., 2009, Bae et al., 2016,
Kobashi et al., 2009) Studies have also reported a higher proportion of indeterminate results in older people. (Kobashi et al., 2009,
Tebruegge et al., 2014, Chee et al., 2008, Kobashi et al., 2008) In
our cohort, we also found that in older people vs adults, there
was a lower concordance between IGRAs, and a higher proportion of indeterminate or borderline results. We found a relationship
between both observations, with discordant results being largely
attributed to inconclusive results. These unclear results hinder a
physician’s ability to recommend LTBI treatment, in particular to
older ReC who have a high risk of progression to active TB disease, and in whom inconclusive results were the highest (17% of
older ReC; Table 1). Importantly, in our cohort we found that the
resolution of inconclusive results was possible in 100% of cases
with a complementary IGRA, yielding a positive or negative result in a timely manner. The resolution of inconclusive results led
to improved concordance in all study groups, including in older
ReC: from a kappa of 0.532 (weak) to 0.800 (strong) (Table S3).
Thus, resolution of inconclusive results by testing with a second
IGRA is a time-eﬃcient alternative when compared with the routine retesting of ReC 8–10 weeks later to conﬁrm if there was a
true conversion to a positive LTBI result. (Mazurek et al., 2005)
The higher risk of active TB development among older people has been largely attributed to their waning immune response.
(Byng-Maddick and Noursadeghi, 2016) For decades, this hypothesis has been based in part on data showing the lower responsiveness of older people to the TST. Our results using IGRAs do not provide support for a marked immunocompromised response to M.tb
antigens in older people. First, we conﬁrmed that the prevalence of
LTBI increases with age in the community, when using IGRAs that
evaluate cell-mediated immunity to M.tb. Second, the magnitude of
the response to M.tb antigens in the CoC or ReC group was compa-

rable between older people and adults who were LTBI positive, and
is consistent with a previous report. (Tebruegge et al., 2014) Third,
the higher proportion of indeterminate results with the QFT in
older people was due to a high IFN-γ background in all cases, and
not to low mitogen responses. Thus, higher indeterminate results
in older people may be a reﬂection of their baseline inﬂammatory status (inﬂammaging) or immune hyper-responsiveness upon
exposure to M.tb antigens. (Piergallini and Turner, 2018) The lack
of an evident compromise in T-cell responses to M.tb in older
people is consistent with ﬁndings from a recent study by our
group. (Ault et al., 2018) Nevertheless, the lower responsiveness of
older people to the T-cell mitogen in the QFT-Plus assay (Table 2)
suggests a generalized defect in cell-mediated immunity, consistent with their reduced responsiveness to vaccines. (Abarca Tomas
et al., 2013)
The higher prevalence of LTBI in older people is thought to be a
major contributing factor to their increased risk of active TB development. (Hochberg and Horsburgh, 2013, Horsburgh et al., 2010)
However, in our cohort, the LTBI prevalence ﬂattened at approximately 70%, with a signiﬁcantly lower proportion of new infections among older people vs adults (Fig. 1). Thus, we posit that
older individuals who are not markedly immunocompromised may
have a higher resistance to LTBI conversion or active TB disease
development compared with adults. There are several observations
supporting this possibility. First, a recent historical review of the
literature among individuals of all ages conﬁrmed that active TB is
more likely to develop shortly after initial infection, with a dwindling risk up to 2 years, and rarely thereafter. Although a case for
older people is not explicitly made, a bimodal distribution for the
risk of TB reactivation is not observed over time. (Behr et al., 2018)
Second, there are studies suggesting that LTBI-positive individuals may be more protected from reinfection with M.tb. (Dutt and
Stead, 1993, Andrews et al., 2012) Third, the interpretation of a
positive LTBI result in individuals with remote exposure is unclear,
with some having a robust recall response to a past LTBI but no
longer harboring viable M.tb. (Behr et al., 2018) Fourth, older people are more likely to have been exposed to M.tb during their
lifetime, even multiple times, and hence, are a select groups of
survivors of active TB and LTBI. (Dutt and Stead, 1993) Thus, the
higher prevalence of positive LTBI tests among older people as a
group is not necessarily a risk factor for active TB disease development, except for individuals who still harbor dormant bacilli
in granulomas and are immunocompromised. Further studies are
needed to understand the relationship between a positive LTBI test
result and the risk of progression to active TB disease, particularly
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for older people with contacts from decades ago. These studies are
critical to guide decisions on LTBI treatment in the older population. (Zevallos and Justman, 2003, Sterling et al., 2020)
We recognize study limitations. First, there is no gold standard
for LTBI assessment, so we based LTBI on positivity with any of the
2 IGRAs tested. Second, we switched from the QFT-GIT to the QFTPLUS kit version during the study; however, 76.1% of the participants were evaluated with the -PLUS kit, and the performance of
both kit versions was similar (Figure S1). The inclusion of both kits
allowed for additional analyses in our cohort and, in our hands, the
TB2 tube in the QFT-PLUS had a minor improvement in sensitivity
(∼2%; Table S4); this was expected given that the tube was added
to improve sensitivity in TB patients. (Petruccioli et al., 2016) Third,
the cross-sectional nature of our design did not allow for the identiﬁcation of the subset of older participants with recent IGRA conversion who are thought to have the highest risk of progression
to active TB disease. Fourth, comparison of new LTBI between ReC
and CoC may be biased by sociodemographic differences that are
associated with higher exposure to M.tb, such as lower education
in the ReC (a proxy for socioeconomic status; Table S1). Finally,
our study included older people with comorbidities such as diabetes and macro- and micro-vascular diseases, but data cannot be
extrapolated to those severely immunocompromised.
Overall, our results suggest that IGRAs are not affected by waning immunity in older people, which contrasts with previous studies using the TST or studies in older people with active TB. Furthermore, despite a higher proportion of discordant or inconclusive
results in older people vs adults, the resolution of inconclusive results was always possible when using a complementary IGRA. This
ﬁnding is not unexpected due to differences between IGRAs in the
technique used (i.e., ﬁxed number of PBMCs per reaction for the
T-SPOT.TB vs ﬁxed volume of blood with QFTs), and the underlying biological difference between a borderline vs an indeterminate result. (T-SPOT.TB Package insert 2017, QuantiFERON-TB Gold
Plus (QFT-Plus) Package Insert 2020) Thus, IGRAs are suitable to
evaluate LTBI in older people. When results of an initial test are inconclusive (borderline or indeterminate), we recommend a repeat
test with the other IGRA, which will likely provide a conclusive result.
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